Published in JAMA Neurol on August 01, 2014
Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol (2014) 2.13
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. JAMA Neurol (2015) 1.52
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol (2015) 1.05
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement (2015) 1.03
Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat (2015) 0.98
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol (2015) 0.95
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. Arch Clin Neuropsychol (2016) 0.88
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol (2015) 0.88
Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest (2016) 0.87
Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study-Cognition Study. Alzheimers Dement (2015) 0.87
Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. JAMA Neurol (2014) 0.85
Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol (2016) 0.84
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. PLoS One (2015) 0.83
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst) (2015) 0.83
Incidence and Impact of Subclinical Epileptiform Activity in Alzheimer's Disease. Ann Neurol (2016) 0.82
Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. Alzheimers Dement (2015) 0.82
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. JAMA Neurol (2016) 0.81
Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis (2015) 0.81
The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis (2016) 0.80
Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimers Dement (N Y) (2017) 0.80
Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther (2016) 0.79
Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study. PLoS Med (2017) 0.79
Brain structure and function as mediators of the effects of amyloid on memory. Neurology (2015) 0.79
Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement (2015) 0.78
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis (2015) 0.78
Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. Neurology (2015) 0.78
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement (2015) 0.77
Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement (2016) 0.76
Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease. Curr Geriatr Rep (2015) 0.76
Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis (2015) 0.76
Which Cognitive Domains are Improved by Treatment with Vortioxetine? Int J Neuropsychopharmacol (2016) 0.75
Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. Cereb Cortex (2017) 0.75
Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol (2017) 0.75
Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Ann Neurol (2016) 0.75
Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. J Prev Alzheimers Dis (2016) 0.75
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement (2016) 0.75
Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study. Front Neurol (2016) 0.75
Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. Nat Commun (2016) 0.75
A Rehabilomics framework for personalized and translational rehabilitation research and care for individuals with disabilities: Perspectives and considerations for spinal cord injury. J Spinal Cord Med (2014) 0.75
Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos. Diabetes Res Clin Pract (2016) 0.75
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res (2016) 0.75
Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials. J Prev Alzheimers Dis (2015) 0.75
Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology (2017) 0.75
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther (2017) 0.75
Imaging plus X: multimodal models of neurodegenerative disease. Curr Opin Neurol (2017) 0.75
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Transl Psychiatry (2017) 0.75
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement (2016) 0.75
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging (2017) 0.75
Design of pilot studies to inform the construction of composite outcome measures. Alzheimers Dement (N Y) (2017) 0.75
Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology (2017) 0.75
Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Front Aging Neurosci (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Simultaneous inference in general parametric models. Biom J (2008) 23.64
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry (1987) 19.45
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol (2000) 4.77
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol (2008) 4.07
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc (2008) 3.21
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Biomarkers in Alzheimer's disease drug development. Alzheimers Dement (2011) 1.97
Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol (1999) 1.93
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology (2013) 1.75
ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord (2006) 1.70
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology (2012) 1.31
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology (2013) 1.11
Sample size estimation for repeated measures analysis in randomized clinical trials with missing data. Int J Biostat (2008) 1.02
Estimating long-term multivariate progression from short-term data. Alzheimers Dement (2014) 0.99
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology (2013) 0.97
Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement (2012) 0.88
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging (2011) 0.86
A new linear model-based approach for inferences about the mean area under the curve. Stat Med (2012) 0.79
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA (2017) 2.58
Common genetic variants influence human subcortical brain structures. Nature (2015) 2.40
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012) 1.97
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal (2013) 1.85
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol (2016) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One (2013) 1.47
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala. Brain (2016) 1.40
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature (2017) 1.39
APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry (2013) 1.37
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol (2012) 1.33
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys (2010) 1.28
Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement (2012) 1.27
Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 1.27
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Simultaneous multi-scale registration using large deformation diffeomorphic metric mapping. IEEE Trans Med Imaging (2011) 1.23
A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis (2011) 1.20
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging (2014) 1.17
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement (2012) 1.16
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct (2013) 1.16
Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurol (2016) 1.15
aBEAT: a toolbox for consistent analysis of longitudinal adult brain MRI. PLoS One (2013) 1.13
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol (2011) 1.13
Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci (2012) 1.10
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Cortical surface reconstruction via unified Reeb analysis of geometric and topological outliers in magnetic resonance images. IEEE Trans Med Imaging (2013) 1.04
Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc (2014) 1.04
Using manifold learning for atlas selection in multi-atlas segmentation. PLoS One (2013) 1.04
A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2013) 1.03
Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav (2012) 1.03
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry (2014) 1.02
Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement (2012) 1.01
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun (2014) 1.01
Transcriptome-guided amyloid imaging genetic analysis via a novel structured sparse learning algorithm. Bioinformatics (2014) 1.01
A sparse structure learning algorithm for Gaussian Bayesian Network identification from high-dimensional data. IEEE Trans Pattern Anal Mach Intell (2013) 1.00
Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging Behav (2012) 0.99
Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med (2015) 0.99
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain (2016) 0.99
The perfect neuroimaging-genetics-computation storm: collision of petabytes of data, millions of hardware devices and thousands of software tools. Brain Imaging Behav (2014) 0.97
Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Mol Psychiatry (2013) 0.97
Cascading network failure across the Alzheimer's disease spectrum. Brain (2015) 0.97
The role of visualization and 3-D printing in biological data mining. BioData Min (2015) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One (2013) 0.96
α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2013) 0.96
A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain (2014) 0.96
Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr (2015) 0.96
Confirmatory factor analysis of the ADNI Neuropsychological Battery. Brain Imaging Behav (2012) 0.95
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol (2015) 0.95
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
A novel relational regularization feature selection method for joint regression and classification in AD diagnosis. Med Image Anal (2015) 0.92
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord (2013) 0.92
Clinical prediction from structural brain MRI scans: a large-scale empirical study. Neuroinformatics (2015) 0.92
Models of the aging brain structure and individual decline. Front Neuroinform (2012) 0.91
Sparse temporally dynamic resting-state functional connectivity networks for early MCI identification. Brain Imaging Behav (2016) 0.91
Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord (2012) 0.91
Effect of cognitive reserve markers on Alzheimer pathologic progression. Alzheimer Dis Assoc Disord (2013) 0.91
Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes (2015) 0.90
CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav (2012) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
Toward a dynamic biomarker model in Alzheimer's disease. J Alzheimers Dis (2012) 0.90
Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav (2013) 0.89
Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. Med Image Anal (2013) 0.89
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis (2015) 0.89
Nonlinear dimensionality reduction combining MR imaging with non-imaging information. Med Image Anal (2011) 0.88
Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One (2013) 0.88
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol (2016) 0.87
Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration. Mol Neurodegener (2013) 0.87
Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PLoS One (2013) 0.87
Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging Behav (2014) 0.87
Genetic architecture of resilience of executive functioning. Brain Imaging Behav (2012) 0.87
Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol (2014) 0.87
The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol (2015) 0.87
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol (2015) 0.87
Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. J Alzheimers Dis (2012) 0.87
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry (2013) 0.86
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res (2014) 0.86
Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport (2013) 0.86
Changes in thalamic connectivity in the early and late stages of amnestic mild cognitive impairment: a resting-state functional magnetic resonance study from ADNI. PLoS One (2015) 0.86
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85